The effect of low-dose esketamine on maternal depression after cesarean delivery.
Saved in:
| Title: | The effect of low-dose esketamine on maternal depression after cesarean delivery. |
|---|---|
| Authors: | Shang, Yan (AUTHOR), Li, Siyuan (AUTHOR), Zheng, Qin (AUTHOR), Mi, Tingting (AUTHOR), Lv, Yuzhu (AUTHOR), Han, Lichun (AUTHOR), Wang, Binrong (AUTHOR) |
| Source: | Journal of Psychosomatic Obstetrics & Gynecology. Dec2025, Vol. 46 Issue 1, p1-14. 14p. |
| Subjects: | Postpartum depression, Edinburgh Postnatal Depression Scale, Clinical trials, Depression in women, Adverse health care events, Cesarean section, Intravenous therapy |
| Abstract: | Objective: To assess the impact of low-dose intravenous esketamine on postpartum depression scores in women undergoing cesarean section. Methods: In a randomized, double-blind, placebo-controlled trial, 186 women aged 20–50 years receiving epidural anesthesia for cesarean section were divided into three groups: Group A (0.25 mg/kg esketamine intraoperatively + esketamine in PCIA), Group B (0.25 mg/kg esketamine intraoperatively + PCIA without esketamine), and Group C (placebo intraoperatively + PCIA without esketamine). The primary outcome was the change in Edinburgh Postnatal Depression Scale (EPDS) scores. Secondary outcomes included Pittsburgh Sleep Quality Index (PSQI) scores, Visual Analogue Scale (VAS) scores, PCIA bolus frequency, and adverse events. Results: EPDS and PSQI scores decreased significantly post-surgery across all groups (p < 0.05). Groups A and B showed greater EPDS score reductions than Group C at 5, 7 and 14 days postoperatively (p < 0.01). No significant differences were observed in PSQI scores, VAS scores or PCIA bolus frequency between groups. Adverse events though mild and transient, were more frequent in Group A (p < 0.01). Conclusion: Low-dose intravenous esketamine, reduces postpartum depression scores post-cesarean section, with a safe profile despite increased mild adverse events when combined with PCIA. [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of Psychosomatic Obstetrics & Gynecology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Objective: To assess the impact of low-dose intravenous esketamine on postpartum depression scores in women undergoing cesarean section. Methods: In a randomized, double-blind, placebo-controlled trial, 186 women aged 20–50 years receiving epidural anesthesia for cesarean section were divided into three groups: Group A (0.25 mg/kg esketamine intraoperatively + esketamine in PCIA), Group B (0.25 mg/kg esketamine intraoperatively + PCIA without esketamine), and Group C (placebo intraoperatively + PCIA without esketamine). The primary outcome was the change in Edinburgh Postnatal Depression Scale (EPDS) scores. Secondary outcomes included Pittsburgh Sleep Quality Index (PSQI) scores, Visual Analogue Scale (VAS) scores, PCIA bolus frequency, and adverse events. Results: EPDS and PSQI scores decreased significantly post-surgery across all groups (p < 0.05). Groups A and B showed greater EPDS score reductions than Group C at 5, 7 and 14 days postoperatively (p < 0.01). No significant differences were observed in PSQI scores, VAS scores or PCIA bolus frequency between groups. Adverse events though mild and transient, were more frequent in Group A (p < 0.01). Conclusion: Low-dose intravenous esketamine, reduces postpartum depression scores post-cesarean section, with a safe profile despite increased mild adverse events when combined with PCIA. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 0167482X |
| DOI: | 10.1080/0167482X.2025.2527659 |
